Overview

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
Hoffmann-La Roche
Sanofi
Treatments:
Capecitabine
Carboplatin
Docetaxel